Gudrun Rebekka Danikas (Jakobsdottir)

🚀 Rezon Bio has officially launched as a standalone European biologics CDMO. Why launch now and does it highlight a growing trend in the industry? Born out of Polpharma Biologics, but now with its own identity, focus, and ambition; a move that reflects where the CDMO market is heading. As CEO Adriana Kiędzierska-Mencfeld put it: “Rezon Bio is a new name, but it stands on a track record that already includes building a broad biosimilars portfolio” For Poland, the benefits go beyond cost-efficiency. The country offers: 🎯 A strong pool of scientific and technical talent 🎯 Growing expertise in biologics and advanced manufacturing 🎯 A location that connects European partners with global supply chains Where many Biologics CDMO's are fighting hard for the best talent, Rezon have looked to capture it's own growing talent pool away from the crowd. For the industry, the implications are clear: ➡️ The market is shifting from generalist divisions inside bigger groups to independent, specialist CDMOs ➡️ Customers are rewarding credibility, focus, and niche expertise ➡️ Talent is becoming the decisive differentiator, not just facilities or capacity The future of pharma services isn’t just about building more plants. It’s about building sharper brands, powered by specialist talent. Congratulations on the launch for the Rezon Bio team!

94

2 Kommentare

💡 Valuable input to the ongoing discussion on equitable access to medicines: Roche CEO Thomas Schinecker highlighted that it would be “very easy” to cut US drug prices by 50%—by removing intermediaries and enabling direct-to-patient distribution. According to Schinecker, half of supply chain earnings currently go to middlemen who take “zero risk” in the innovation process. This dialogue underscores a key challenge: ensuring broad access to life-saving therapies while preserving the necessary incentives for those who invest heavily and take the scientific and financial risks to innovate for patients in need. HealthcarePolicy #PharmaInnovation #DrugPricing #AccessToMedicine #Biopharma

83

8 Kommentare

When I was a teenager, my aunt gave me one of the books that had the greatest impact on my life. In the fast-paced world we live in, it's easy to lose sight of what truly matters. Michael Ende's timeless novel Momo offers profound insights into the value of time, the power of listening, and the importance of authenticity - lessons that resonate deeply in our personal and professional lives. Here are four key takeaways I would like to share with you, that can inspire us to create a more meaningful and balanced work environment: ⏳ Value of Time: Momo teaches us to cherish time, reminding us to prioritize meaningful tasks over being perpetually "busy." In our work environment, focus on impactful activities that align with long-term goals rather than reactive, short-term demands. 👂 Deep Listening: Momo's ability to truly listen highlights the importance of empathetic communication. Actively listening to colleagues and team members fosters trust, collaboration, and innovative problem-solving. 🚫 Resisting External Pressures: The "Men in Grey" symbolize the dangers of external pressures to overperform. In our workplace, we should resist the urge to overcommit and instead maintain a healthy balance that sustains productivity and well-being. 🌟 Authentic Leadership: Momo's journey underscores the power of authenticity. As leaders, we should inspire by example, valuing genuine connections and empowering our teams to thrive in a supportive, purpose-driven environment. Momo reminds us that success isn't just about doing more, it's about doing what truly matters, in the right way. Let’s take these lessons to heart and build a workplace where time, connection, and authenticity are valued. #Leadership #WorkplaceCulture #TimeManagement #Empathy #Authenticity

57

2 Kommentare

Where do we stand on the Section 232 investigation in pharmaceuticals – and what should the EU do? The announcement on U.S. tariffs is a reminder that we cannot take the global competitiveness of Europe’s pharmaceutical and biotech sector for granted. For decades, medicines were rightly excluded from tariffs under WTO rules. Now, with a 15% cap in place, innovation has been disadvantaged — while generics were prioritized. But without innovation, there are no generics. We appreciate that the European Commission has taken the importance of pharmaceuticals into account and avoided reciprocal tariffs on finished medicines. A compromise was needed — but the real question is how Europe responds. 👉 The answer must be competitiveness. That means not only adopting new initiatives such as the Biotech Act, the Critical Medicines Act and the pharma package — but also making sure they work together coherently. 👉 It also means enforcing existing legislation, like the Transparency Directive, and implementing the EU HTA system in a way that is scientifically sound and genuinely welcomes innovation. 👉 And it means addressing looming risks like “most favoured nation” pricing, which could impact patient access just as seriously as tariffs. If Europe wants to remain an attractive home for R&D, manufacturing, and biotech clusters, it must provide predictability in reimbursement and ensure incentives for innovators. Otherwise, we risk seeing the kinds of access problems already visible in the UK, where a breast cancer medicine was recently not made available to patients due to the financial environment. The next months will be decisive. Europe has the chance to build an innovation-friendly framework that strengthens its pharmaceutical and biotech sector — not undermine it. https://lnkd.in/eFtbUHNy

60

1 Kommentar